Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers
Brief Summary: Rotavirus is the leading cause of severe diarrhea in infants and young children, accounting for 45% of severe diarrhea disease in both developed and developing countries. Annually, rotavirus causes approximately 111 million episodes of gastroenteritis requiring home care, 25 million clinic visits, 2 million hospitalizations, and approximately 440,000 deaths in children less than 5 years of age, of which approximately 90% of hospitalizations and 99% of deaths occur in developing countries. Although rotavirus infection is not more common in HIV-infected children, it complicates their care and interferes with their nutrition. Chances of death by these infections can be greater in HIV-infected children when they also suffer from wasting, malnutrition, and/or opportunistic infections. The primary purpose of this study was to evaluate the safety and immunogenicity of the Rotavirus vaccine candidate, RotaTeq, in HIV-infected and uninfected children born to HIV-infected mothers.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
B: Arm Label: Rotavin2H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin2L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3H; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotavin3L; Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotavin2H, Rotavin2L, Rotavin3H, Rotavin3L
C: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
D: Arm Label: Group 1 - BRV-PV Lot A; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot A + DPT-HepB-Hib + OPV | Arm Label: Group 2 - BRV-PV Lot B; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot B + DPT-HepB-Hib + OPV | Arm Label: Group 3 - BRV-PV Lot C; Type: EXPERIMENTAL; Interventions: Biological: BRV-PV Lot C + DPT-HepB-Hib + OPV | Arm Label: Group 4 - ROTARIX; Type: ACTIVE_COMPARATOR; Interventions: Biological: ROTARIX + DPT-HepB-Hib + OPV | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot A + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 1 - BRV-PV Lot A | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot B + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 2 - BRV-PV Lot B | Intervention Type: BIOLOGICAL; Name: BRV-PV Lot C + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 3 - BRV-PV Lot C | Intervention Type: BIOLOGICAL; Name: ROTARIX + DPT-HepB-Hib + OPV; Assigned to Arm(s): Group 4 - ROTARIX

Answer: C